Leuner Kristina, Kurz Christopher, Guidetti Giorgio, Orgogozo Jean-Marc, Müller Walter E
Department of Pharmacology, Biocenter, University of Frankfurt Frankfurt, Germany.
Front Neurosci. 2010 Sep 7;4. doi: 10.3389/fnins.2010.00044. eCollection 2010.
Piracetam, the prototype of the so-called nootropic drugs' is used since many years in different countries to treat cognitive impairment in aging and dementia. Findings that piracetam enhances fluidity of brain mitochondrial membranes led to the hypothesis that piracetam might improve mitochondrial function, e.g., might enhance ATP synthesis. This assumption has recently been supported by a number of observations showing enhanced mitochondrial membrane potential, enhanced ATP production, and reduced sensitivity for apoptosis in a variety of cell and animal models for aging and Alzheimer disease. As a specific consequence, substantial evidence for elevated neuronal plasticity as a specific effect of piracetam has emerged. Taken together, this new findings can explain many of the therapeutic effects of piracetam on cognition in aging and dementia as well as different situations of brain dysfunctions.
吡拉西坦是所谓的促智药的原型，多年来在不同国家用于治疗衰老和痴呆中的认知障碍。吡拉西坦可增强脑线粒体膜流动性的发现引发了这样的假说，即吡拉西坦可能改善线粒体功能，例如可能增强ATP合成。最近，这一假设得到了一些观察结果的支持，这些观察结果表明，在各种衰老和阿尔茨海默病的细胞和动物模型中，线粒体膜电位增强、ATP产生增加以及对细胞凋亡的敏感性降低。作为一个具体结果，有大量证据表明，吡拉西坦具有提高神经元可塑性的特定作用。综上所述，这些新发现可以解释吡拉西坦对衰老和痴呆认知以及不同脑功能障碍情况的许多治疗作用。
